WO2013019058A3 - Pharmaceutical composition for inhibiting cancer recurrence or metastasis - Google Patents

Pharmaceutical composition for inhibiting cancer recurrence or metastasis Download PDF

Info

Publication number
WO2013019058A3
WO2013019058A3 PCT/KR2012/006096 KR2012006096W WO2013019058A3 WO 2013019058 A3 WO2013019058 A3 WO 2013019058A3 KR 2012006096 W KR2012006096 W KR 2012006096W WO 2013019058 A3 WO2013019058 A3 WO 2013019058A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastasis
cancer
recurrence
present
pharmaceutical composition
Prior art date
Application number
PCT/KR2012/006096
Other languages
French (fr)
Other versions
WO2013019058A2 (en
Inventor
Sung-Wuk Kim
Chang-Hee Min
Ja-Seong Koo
Sang-Ouk Sun
Yong-Eun Kim
Original Assignee
Hanall Biopharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co., Ltd. filed Critical Hanall Biopharma Co., Ltd.
Publication of WO2013019058A2 publication Critical patent/WO2013019058A2/en
Publication of WO2013019058A3 publication Critical patent/WO2013019058A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for inhibiting cancer recurrence or metastasis and a method for inhibiting cancer recurrence or metastasis using the same. The present invention identified the activity of 2-deoxy-D-glucose (2-DG, below) for the inhibition of mammosphere formation and EMT, indicating its inhibitory effect against proliferation of cancer stem cell and cancer metastasis, which has not been known hitherto. The present invention also identified that the combined use of a biguanide based antidiabetic agent or its pharmaceutically acceptable salt and 2-DG can inhibit cancer metastasis and steeply decrease cancer recurrence in comparison to the single use of said active ingredients, resulting in a superior effect in the inhibition of cancer metastasis and recurrence when the same dosage is applied. Therefore, the pharmaceutical composition of the present invention can be used to show substantially more excellent effect with less amount of each active ingredient, reducing the side effects due to the use of excess drug and due to their pharmacological action, and providing more efficacious treatment. Moreover, when it is used along with an anticancer agent to which resistance is shown, it is expected that more synergistic effect can be exhibited. Therefore, the pharmaceutical composition and method for inhibiting cancer recurrence or metastasis according to the present invention can be used very advantageously for the treatment and prevention of metastasis or recurrence of various cancer diseases.
PCT/KR2012/006096 2011-08-04 2012-07-31 Pharmaceutical composition for inhibiting cancer recurrence or metastasis WO2013019058A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110077794A KR101900478B1 (en) 2011-08-04 2011-08-04 Pharmaceutical composition for inhibiting cancer recurrence or metastasis
KR10-2011-0077794 2011-08-04

Publications (2)

Publication Number Publication Date
WO2013019058A2 WO2013019058A2 (en) 2013-02-07
WO2013019058A3 true WO2013019058A3 (en) 2013-04-04

Family

ID=47629794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006096 WO2013019058A2 (en) 2011-08-04 2012-07-31 Pharmaceutical composition for inhibiting cancer recurrence or metastasis

Country Status (2)

Country Link
KR (1) KR101900478B1 (en)
WO (1) WO2013019058A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101471274B1 (en) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Biomarker composition for diagnosis of bortezomib resistance comprising mitochondrial calcium uniporter and diagnostic kit using the same
JP6489517B2 (en) * 2013-05-14 2019-03-27 国立大学法人山形大学 Differentiation-promoting agents and brain tumor therapeutic agents for cancer stem cells
CN104161759B (en) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 The anticancer usage of anagrelide and its derivative
WO2015026215A1 (en) * 2013-08-23 2015-02-26 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
KR101642587B1 (en) 2013-08-23 2016-07-25 가톨릭대학교 산학협력단 Pharmaceutical composition for prevention or treatment of immune diseases or inflammatory disease comprising biguanide derivative compounds
CN104352518A (en) * 2014-10-22 2015-02-18 王喜功 Orally-taken chemotherapy tablet for treating stomach cancer
ES2743493T3 (en) * 2014-10-29 2020-02-19 Haimbio Co Ltd Composition for the treatment of cancer stem cells
WO2016126073A2 (en) * 2015-02-02 2016-08-11 연세대학교 산학협력단 Pharmaceutical composition for inhibiting growth of cancer stem cells, containing aldehyde inhibitor and biguanide-based compound
KR101765575B1 (en) * 2015-02-02 2017-08-07 연세대학교 산학협력단 Pharmaceutical composition for inhibiting a growth of cancer stem cells comprising aldehyde inhibitor and biguanide compounds
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
KR102666477B1 (en) 2015-07-31 2024-05-17 더 존스 홉킨스 유니버시티 Prodrugs of glutamine analogues
CN108348492B (en) * 2015-07-31 2021-09-28 约翰霍普金斯大学 Methods for cancer and immunotherapy using glutamine analogs
CN106466305A (en) * 2016-08-26 2017-03-01 四川大学 Metformin is used for purposes and pharmaceutical composition in preparation treatment and/or prevention head and neck scale carcinoma medicine
US20200138840A1 (en) * 2017-06-28 2020-05-07 Kawasaki Gakuen Educational Foundation Pharmaceutical composition and tumor immunoactivity promoter
CN108451904B (en) * 2018-05-21 2021-02-09 中国农业科学院农产品加工研究所 Potassium oxonate stable suspension and preparation method thereof
KR102260846B1 (en) * 2018-07-09 2021-06-07 국립암센터 Pharmaceutical composition for prevention or treatment of cancer comprising gossypol, phenformin and anti-cancer drug
KR102141971B1 (en) * 2018-11-12 2020-08-06 주식회사 노암 Anticancer composition
RU2707554C1 (en) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Composition inhibiting tumor growth and survival rate
WO2020213939A1 (en) * 2019-04-15 2020-10-22 주식회사 진센 Pharmaceutical composition for co-administration of anticancer drug
KR102422090B1 (en) * 2019-09-25 2022-07-20 연세대학교 산학협력단 A pharmaceutical composition for preventing or treating cancer comprising yap-tead interaction inhibitor and hypoglycemic agent
WO2021060944A1 (en) * 2019-09-25 2021-04-01 연세대학교 산학협력단 Pharmaceutical composition for preventing or treating cancer comprising yap-tead interaction inhibitor and hypoglycemic agent
KR102312100B1 (en) * 2020-06-05 2021-10-14 (주)프론트바이오 Pharmaceutical composition for preventing or treating cancer comprising antivirals, and antidepressants thereof as active ingredients
KR102562739B1 (en) * 2020-09-11 2023-08-03 연세대학교 산학협력단 Pharmaceutical composition for the death of cancer origin cell
KR20230018341A (en) * 2021-07-29 2023-02-07 (주)프론트바이오 Pharmaceutical composition for preventing or treating cancer comprising antivirals, and antidepressants thereof as active ingredients
KR102714321B1 (en) * 2021-11-11 2024-10-10 주식회사 노암 Anticancer composition comprising cancer metabolism regulator

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082301A1 (en) * 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
US20040167079A1 (en) * 2003-01-10 2004-08-26 George Tidmarsh Treatment of cancer with 2-deoxyglucose
US20050020682A1 (en) * 2003-06-12 2005-01-27 Newell M. Karen Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20100260733A1 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti aging agents and methods to identify them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082301A1 (en) * 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
US20040167079A1 (en) * 2003-01-10 2004-08-26 George Tidmarsh Treatment of cancer with 2-deoxyglucose
US20050020682A1 (en) * 2003-06-12 2005-01-27 Newell M. Karen Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20100260733A1 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti aging agents and methods to identify them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAHRA, I. B. ET AL.: "Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells", CANCER RESEARCH, vol. 70, no. ISSUE, 2010, pages 2465 - 2475 *

Also Published As

Publication number Publication date
KR101900478B1 (en) 2018-09-20
WO2013019058A2 (en) 2013-02-07
KR20130015669A (en) 2013-02-14

Similar Documents

Publication Publication Date Title
WO2013019058A3 (en) Pharmaceutical composition for inhibiting cancer recurrence or metastasis
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2015194764A3 (en) Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
RU2018135973A (en) PHARMACEUTICAL COMBINATION CONTAINING METROFORMIN AND DYHYDROQUERCENINE, AND ITS APPLICATION FOR TREATING CANCER
WO2012139081A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2011159100A3 (en) Anti-cancer pharmaceutical composition
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012148174A3 (en) Composition for topical application for preventing hair loss and stimulating hair growth
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX2018000084A (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin.
EP2796450A4 (en) 6-aminopyridine-3-ol derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same as active ingredients for preventing or treating diseases caused by angiogenesis
WO2020159171A3 (en) Composition comprising streptonigrin and anticancer agent for preventing or treating colorectal cancer
WO2011149288A2 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
MX2013014071A (en) A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck.
WO2012064159A3 (en) Anticancer composition
WO2013074273A8 (en) Bidens pilosa and polyacetylenic compounds for prevention and treatment of coccidiosis
WO2013022257A3 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
WO2016108572A3 (en) Composition for preventing and treating cholesterol-related diseases
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
MX2014006662A (en) Targeting en2, pax2, and/or defb1 for treatment of prostate conditions.
EP3417869A4 (en) Composition containing phragmitis rhizoma extract as active ingredient for preventing, ameliorating, or treating disease attributed to side effect of anticancer agent
WO2014007549A3 (en) Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12819318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12819318

Country of ref document: EP

Kind code of ref document: A2